Primary source: Inspections and Compliance
Daraxonrasib has been officially approved for use in treating metastatic pancreatic adenocarcinoma, necessitating updates to product labeling and safety communications.
This approval offers a new treatment option for a hard-to-treat cancer, potentially improving outcomes for patients with specific genetic mutations and prior treatment history.
Healthcare professionals must include daraxonrasib in adverse event reporting as the new treatment option is now available for eligible patients.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Healthcare professionals must include daraxonrasib in adverse event reporting as the new treatment option is now available for eligible patients.
On August 26, 2026, the FDA approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The drug demonstrated significant improvements in overall and progression-free survival compared to standard chemotherapy regimens in clinical trials.
What changed: Daraxonrasib has been officially approved for use in treating metastatic pancreatic adenocarcinoma, necessitating updates to product labeling and safety communications.
Why it matters: This approval offers a new treatment option for a hard-to-treat cancer, potentially improving outcomes for patients with specific genetic mutations and prior treatment history.
Practical implication: Healthcare professionals must include daraxonrasib in adverse event reporting as the new treatment option is now available for eligible patients.
Published from the regulator source ingestion pipeline after PV impact triage.
Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.
Affected healthcare facilities should remove all Automated Impella Controllers from use and stock, ensure annual preventive maintenance is followed, and report any adverse reactions to Abiomed or MedWatch.
Facilities using these devices must immediately cease their use, segregate them from other stock, and return them to Boston Scientific. Relevant personnel must be notified of this recall.
Small business dispensers are encouraged to complete a mandatory assessment survey by September 22, 2026, and do not need to submit information to the FDA while utilizing these exemptions.
